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Abstract: Pharmacotherapies for opioid addiction under active development in the US include 
lofexidine (primarily for managing withdrawal symptoms) and Probuphine®, a distinctive mode 
of delivering buprenorphine for six months, thus relieving patients, clinicians, and regulatory 
personnel from most concerns about diversion, misuse, and unintended exposure in children. 
In addition, two recently approved formulations of previously proven medications are in early 
phases of implementation. The sublingual film form of buprenorphine + naloxone  (Suboxone®) 
provides a less divertible, more quickly administered, more child-proof version than the 
buprenorphine + naloxone sublingual tablet. The injectable depot form of naltrexone (Vivitrol®) 
ensures consistent opioid receptor blockade for one month between administrations, removing 
concerns about medication compliance. The clinical implications of these developments have 
attracted increasing attention from clinicians and policymakers in the US and around the world, 
especially given that human immunodeficiency virus/acquired immunodeficiency syndrome and 
other infectious diseases are recognized as companions to opioid addiction, commanding more 
efforts to reduce opioid addiction. While research and practice improvement efforts continue, 
reluctance to adopt new medications and procedures can be expected, especially considerations 
in the regulatory process and in the course of implementation. Best practices and improved 
outcomes will ultimately emerge from continued development efforts that reflect input from 
many quarters.
Keywords: buprenorphine, naltrexone, probuphine, lofexidine, implant buprenorphine, 
buprenorphine film
Introduction
In late 2011, the only medications for opioid addiction under active development in 
the US are lofexidine (licensed as Britlofex® in the UK, primarily for detoxification) 
and depot buprenorphine as Probuphine®. The development of Probuphine is a testa-
ment to the clinical success of sublingual buprenorphine; there would have been no 
Probuphine development had buprenorphine been a clinical failure. The need for the 
long-acting formulation is also an indication of the concerns about medication non-
adherence and the potential for diversion of sublingual buprenorphine. Lofexidine is 
an α2-adrenergic receptor agonist that has been approved for opioid withdrawal in 
the UK and used for almost two decades, but it is not yet approved for that indication 
in the US. Because lofexidine is not an opioid, it is politically attractive and socially 
more palatable, but its clinical viability remains in question. In addition to its potential 
role in opioid detoxification, lofexidine may turn out to be useful for buprenorphine-
maintained patients desiring to taper and discontinue buprenorphine.
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A recent addition to the armamentarium for opioid 
 addiction is the injectable depot formulation of the opioid 
antagonist naltrexone, marketed as Vivitrol®. Approved by 
the US Food and Drug Administration in October 2010 for 
opioid addiction, so technically beyond the development stage, 
 Vivitrol is included in this review because its clinical utility 
is yet to be fully explicated, with only one full-scale trial to 
document its use for opioid addiction.1 We also discuss the 
 sublingual film form of buprenorphine combined with nalox-
one, marketed as Suboxone®, recently made available in an 
effort to provide a less divertible, more child-proof version than 
the buprenorphine + naloxone tablet. The clinical implications 
of these developments for treatment of opioid addiction have 
attracted increasing attention from clinicians and policymakers 
in the US and around the world, especially as human immuno-
deficiency virus (HIV)/acquired immunodeficiency syndrome 
(AIDS) and other infectious diseases are recognized as close 
companions to opioid addiction, driving more efforts to reduce 
opioid addiction and its consequences.
Lofexidine
Lofexidine is an antihypertensive medication that has also been 
used in Britain and elsewhere for reducing opioid withdrawal 
symptoms. Research has found that lofexidine is useful in 
managing opioid withdrawal symptoms during detoxification 
from heroin and methadone, as documented in two Cochrane 
reviews.2,3 Based on the meta-analyses, the authors concluded 
that “lofexidine has a better safety profile than clonidine”, a 
similar medication with a longer history of off-label use in 
managing opioid withdrawal in the US and elsewhere, but one 
that often causes hypotension, sedation, and risk of rebound 
hypertension. A more recent review4 confirmed the less fre-
quent incidence and lower severity of adverse events with 
lofexidine, particularly in terms of hypotension, in comparison 
with clonidine (Catapress®) used for opioid detoxification. 
Those reviews confirmed earlier work examining five trials 
in which safety, efficacy, and tolerability of lofexidine were 
found superior to clonidine.5 One of the studies was notable 
for its inclusion of heroin addicts not previously stabilized, 
among whom dropout from lofexidine was greater than in the 
other trials of opioid-maintained patients.6
In another study designed to determine the efficacy of 
lofexidine as a detoxification medication, investigators 
enrolled 68 opioid addicts (on heroin, morphine, or hydro-
morphone) who were then stabilized for 3 days on a fixed 
dose of morphine followed by either 5 days of lofexidine or 
placebo by random assignment.7 With better retention and 
with significantly fewer and less severe withdrawal symptoms 
among the lofexidine group, the trial was halted on ethical 
grounds. Side effects associated with lofexidine included 
dizziness, hypotension, lassitude, and insomnia. Findings 
from that research in the US were also consistent with the 
earlier reviews5 of lofexidine trials in Taiwan and in Britain, 
where lofexidine has been approved since 1992 for opioid 
withdrawal treatment.
Being a nonopioid makes lofexidine a promising candidate 
in medication development efforts, especially  considering 
its ability to reduce withdrawal symptoms safely with fewer 
side effects than clonidine and with efficacy that is comparable 
with opioid agonist or partial agonist medications (methadone, 
buprenorphine) sometimes used in detoxification. To move 
lofexidine forward in the US, the manufacturer’s licensee (US 
World Meds Inc) has proposed research to be conducted in 
a cooperative agreement arrangement with the US National 
Institute on Drug Abuse to replicate findings confirming the 
effectiveness of lofexidine in reducing opioid withdrawal 
symptoms. In accord with the position of the US Food and 
Drug Administration, the research would likely emphasize 
additional assessment of withdrawal symptoms according to 
subjective measures, eg, the Short Opiate Withdrawal Scale8 
or the Clinical Opiate Withdrawal Scale,9,10 instead of the 
Modified Himmelsbach Opioid Withdrawal Scale, as used 
by Yu et al.7
Probuphine: buprenorphine implant
Buprenorphine for opioid addiction
Buprenorphine is a partial mu opioid receptor agonist 
approved by the US Food and Drug Administration (FDA) in 
October, 2002 as a pharmacotherapy for the treatment of opi-
oid addiction.11 Controlled clinical trials in several thousand 
patients over the past 15 years have provided strong support 
for its therapeutic efficacy.12–17 Suboxone, a sublingual com-
bination tablet containing buprenorphine and naloxone (an 
opioid antagonist) was developed to mitigate injection use.
As an office-based pharmacotherapy, buprenorphine 
allows patients to receive medication by prescription to 
be taken at home, thereby avoiding daily attendance at a 
traditional opioid treatment program. Buprenorphine has 
been well received in the US, Australia, and Europe, increas-
ing the number of patients seeking treatment for opioid 
addiction because of its availability at private physicians’ 
offices, its less restrictive controls, and its favorable safety 
profile.16–20 Compared with full mu agonists, buprenorphine 
has the advantage of limited dose-dependent euphoria and 
less respiratory depression at higher doses because of the 
ceiling effect.
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In 2007, more than two million prescriptions for 
 buprenorphine were issued to about 300,000 patients in the 
US, and more than 14,000 physicians have been authorized to 
prescribe buprenorphine for opioid addiction.21 This compares 
with about 268,000 patients in 2008 on daily methadone, which 
was introduced 40 years ago. As evidenced by its proven effi-
cacy, its widespread uptake by clinicians, and its acceptance 
among patients, buprenorphine looks to be a success. It is 
arguably the most significant advance in the treatment of opioid 
addiction since the introduction of methadone. Buprenorphine 
is not an unqualified success, however, because the successful 
adoption of the sublingual tablet formulation has come with 
its own price, ie, diversion, misuse, inconsistent compliance, 
and accidental poisoning from unintended exposure. Seeking 
to enhance effective delivery and to counter some of these 
problems, advances in medication development led to the 
development of other preparations, ie, the film and implant 
forms of buprenorphine (Probuphine).
Probuphine
The Probuphine form of buprenorphine employs the ProNeura 
long-term drug delivery system,22 consisting of a small, solid 
“rod” made from a mixture of ethylene vinyl acetate and the 
equivalent of about 80 mg of buprenorphine, reliably released 
at a measured rate according to the matrix diffusion. The rod is 
placed subdermally in the upper arm in a 15-minute, procedure 
in the office, and is removed in a similar manner at the end of 
the treatment period.  Probuphine eliminates the need for daily 
dosing and reliably provides a sustained and constant blood 
concentration lasting through six months, thereby reducing 
or eliminating use of illicit opioids. The standard implant 
dose, following the manufacturer’s brochure, is four rods, 
with a fifth and sixth rod added if additional medication is 
needed according to the  physician’s assessment. Patients are 
first inducted onto sublingual buprenorphine for 3–7 days in 
preparation for the implant of Probuphine rods.
Research has documented the safety and acceptability 
of the transition from sublingual buprenorphine to the 
Probuphine implant formulation.22 In a six-month placebo-
controlled trial involving 163 patients randomized 2:1 
(Probuphine:placebo), the study showed that patients assigned 
to Probuphine implants, compared with those assigned to 
placebo, had less illicit opioid use over weeks 1–16, 17–24, 
and 1–24.23 The Probuphine group also had better retention, 
fewer withdrawal symptoms, lower craving scores, and bet-
ter global clinical improvement by patient and investigator 
assessments. With Probuphine’s depot delivery providing 
reliable pharmacotherapeutic effects over a six-month period, 
medication compliance is assured and medication diversion 
or misuse is eliminated.
Preliminary findings were recently released from a Phase III 
study of Probuphine confirming the safety and efficacy, 
comparing Probuphine with placebo and with active drug 
(Suboxone) over a 24-week period.24 Statistically signifi-
cant results were found for the two primary endpoints, ie, 
 percentages of urine samples testing negative for illicit opioid 
use over the 24-week treatment period (P , 0.0001), and 
congruence of urine toxicology with patient self-reported 
opioid use (P , 0.0001). Notably, Probuphine efficacy was 
confirmed as noninferior to the Suboxone form of buprenor-
phine at 12–16 mg/day.
Research continues in order to collect the additional data 
necessary for the submission of a New Drug Application to 
the FDA. Topics of interest in future research include the 
need for additional rods to be implanted if dosage does not 
appear to alleviate withdrawal symptoms entirely, and the 
issue of taper from buprenorphine once the implants have 
been removed, depending on remaining blood levels of 
buprenorphine and potential for withdrawal.
Vivitrol: injectable, extended-release 
naltrexone
Naltrexone, an effective but  
underutilized medication
For three decades, the opioid antagonist, naltrexone (ReVia®), 
has been demonstrated to be a safe and effective orally 
administered pharmacotherapy for opioid addiction.25–32 
Naltrexone and its active metabolite, 6-β-naltrexol, are com-
petitive antagonists at the mu opioid receptors, which is the 
mechanism of action for the management of opioid addiction. 
Naltrexone blockade or attenuation of the reinforcing effects 
of subsequently administered opioids theoretically leads to 
extinction of opioid-taking behaviors over time, aided by 
behavioral therapy. Naltrexone is not addictive, affords no 
agonist effects, and is not sedating.
The pharmacologic efficacy of naltrexone has not yielded 
commensurate clinical success for treatment of opioid addic-
tion because of poor patient compliance and high rates of 
treatment dropout.33 In a trial of three times weekly naltrex-
one for heroin addiction, only 10 of 108 enrolled patients 
remained in treatment for 14 weeks, and 74 either never 
started dosing or had so few doses that no blockade was in 
effect.34 Furthermore, noncompliance and patient-initiated 
termination of naltrexone therapy have been associated 
with opioid overdose, and at a rate higher than occurs with 
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 methadone treatment,35–37 possibly due to decreased  tolerance 
or receptor supersensitivity following prolonged opioid 
receptor blockade. Improved compliance has been noted in 
certain highly motivated subsamples of opioid addicts,38–41 
as well in programs that include psychosocial therapy,42,43 
including contingency management.44,45
To counter the problems of compliance and premature 
discontinuation typical of oral naltrexone, development of 
depot naltrexone (by implant and by injection) represents an 
important advance in the treatment of opioid dependence. As 
demonstrated in work to determine clinical dosing by Comer 
et al,46–48 384 mg naltrexone delivered in sustained-release 
depot formulation blocked the reinforcing, subjective, and 
physiological effects of up to 25 mg heroin, and provided 
therapeutic plasma levels for approximately 30 days.49–51 
Importantly, at this dose, naltrexone resulted in better than 80% 
retention in treatment at six weeks versus 40% for placebo.48 
In comparison with the oral formulation, depot naltrexone 
showed significantly higher rates of abstinence and better treat-
ment outcomes at 12-month follow-up.52 Adverse events were 
minimal and limited to local responses at the injection site.53
Extended-release injectable formulation
First approved for treatment of alcohol abuse, Vivitrol is an 
extended-release formulation of naltrexone injected once 
monthly (every four weeks), with peak drug concentrations 
occurring at 2 hours and again at 2–3 days. Concentrations 
slowly decline after 14 days, remaining at therapeutic levels 
through 30 days, with metabolites continuing to be detect-
able after one month. The most common adverse events asso-
ciated with Vivitrol in clinical trials were nausea, vomiting, 
headache, dizziness, asthenic conditions, and injection site 
reactions. In addition to possible hepatic toxicity, naltrexone 
and other opioid receptor antagonists used over the long term 
can increase sensitivity of the opioid receptors, which con-
tinues for some duration following cessation. An increased 
potential thereby exists for overdose in the case of illicit 
use of opioids following cessation of long-term naltrexone 
therapy. In the event of need for opioid pain medication, 
the manufacturer recommends regional analgesia or the 
use of nonopioids.
The Vivitrol extended-release formulation has been 
found safe and well tolerated for participants in studies of 
alcoholics54–56 and was approved for this indication by the 
FDA in 2006. Other research found that 384 mg of extended-
release naltrexone resulted in “minimal and generally mild” 
adverse events and that the formulation was “well tolerated” 
by combination opioid and stimulant users.48
A randomized, placebo-controlled, double-blind trial of 
Vivitrol was conducted in Russia, where agonist replacement 
therapy is not available.1 Participants were first detoxified in 
inpatient settings for less than 30 days to ensure at least 7 days 
of opioid abstinence. Participants received monthly intra-
muscular injections of Vivitrol 380 mg (n = 126) or  placebo 
(n = 124) for four months with 12 biweekly counseling 
 sessions. The number of weeks of confirmed abstinence based 
on rate of opioid-negative urine drug tests and self-report of 
nonuse during weeks 5–24 was the primary outcome. In the 
Vivitrol group, a median 90% confirmed abstinent weeks dur-
ing weeks 5–24 versus 35% for placebo (P = 0.0002). More 
opioid-free days were reported by the Vivitrol participants 
(P = 0.0004; 99.2% versus 60.4% of placebo participants). 
Vivitrol participants were retained in the study more than 
168 days on average compared with 96 days for placebo 
participants (P = 0.0042). Craving was reduced 50% from 
baseline levels in the Vivitrol group, whereas there was no 
change in the placebo group. No Vivitrol participants died, 
overdosed, or ended participation due to severe adverse 
events associated with the study protocol.
Buprenorphine sublingual film
The manufacturer of Suboxone (Reckitt Benckiser Pharma-
ceuticals, Richmond, VA) gained FDA approval in August 
2010 for its buprenorphine film designed to reduce diversion 
and to reverse the troubling rise in unintentional exposure in 
children. The US Drug Abuse Warning System documented 
that 94% of presentations to emergency departments for acci-
dental ingestion of buprenorphine in 2009 involved children 
under the age of six years.57 The Suboxone and Subutex® tablet 
formulations may appear similar to candy, as hypothesized in 
recent literature to be a factor in the high rate of accidental 
ingestion by children.58 More than 95% of accidental child 
exposures result from parental carelessness with the handling 
of their medications, primarily from not properly storing the 
medication away from children. It is unclear whether the widely 
held perception of buprenorphine’s general safety may con-
tribute to carelessness with medication storage and handling. 
The safety of the film strip has been tested for the Consumer 
Product Safety  Commission, showing that one child out of 50 
was able to open two or more of the film pouches.59
The key features of the film are that it is less prone to inges-
tion by young children because of its restrictive packaging, it is 
clinically interchangeable with the sublingual tablet forms, and 
is more quickly dissolved and better tasting, so is acceptable 
to patients familiar with the tablet form. The film packaging 
contains unique identifier information in barcode format, 
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allowing authorities to track sourcing of diverted supplies. 
Furthermore, the interchangeability has allowed a continuity of 
practice in terms of dosage during treatment. In many countries 
(eg, Australia, UK), supervised dosing is required, at least at 
the start of treatment, so the reduced dosing time of the film 
means less supervision required by clinical staff. Still, the film 
can be considered only a partial success at this point after being 
made available in October 2010. Patient preference for the film 
is not universal and it is too early to determine whether the film 
formulation has had the desired effect on unintentional exposure 
among children. The nature of the film cannot mitigate misuse, 
noncompliance, and diversion.
Commentary
Implications for clinical practice in regions 
with established addiction treatment
Although only a few really promising medications for opioid 
addiction are likely to be approved in the near term, there is 
some cause for celebrating those developments as significant. 
Lofexidine will be a valuable medication if it proves out 
as a workable means of alleviating withdrawal symptoms, 
accomplished with fewer side effects than clonidine, the 
medication for opioid detoxification more commonly used 
in the US. Getting addicts into treatment may be much easier 
given the prospect of a less grueling detoxification with with-
drawal symptoms well controlled by a lofexidine regimen of 
several days. Even then, lofexidine for managing opioid with-
drawal symptoms would not likely displace buprenorphine 
as a means of assisting detoxification except in cases where 
patients and clinicians eschew opioids, even a partial opioid 
agonist. For those patients who are willing to remain on a 
partial opioid agonist (as in substitution therapy) or who have 
been unable to adhere to an antagonist protocol, Probuphine 
(buprenorphine implant) offers a distinctive new formulation 
of a proven medication that would appear to relieve patients, 
clinicians, and regulatory personnel from the burden of diver-
sion,  misuse, and unintended exposure in children.
An implantable or injectable depot formulation of an 
effective medication might be considered an optimum 
approach, considering the resulting negation of medication 
nonadherence, misuse, and diversion, but this may not be an 
opinion shared by some addiction medicine clinicians and 
patients. Those who are familiar with the initial efforts to 
use depot naltrexone as an opioid addiction treatment can be 
forgiven for not being early enthusiasts of Probuphine, despite 
its apparent advantages. Their recollections are dominated by 
the almost universal difficulties in attracting individuals to the 
antagonist medication, which is understandable, given the 
fact that patients disliked taking the oral medication and were 
leery of a long-acting form. This is not the case with buprenor-
phine, being a partial agonist. Instead, the converse problem 
arose with sublingual buprenorphine, which can happen 
when patients like their medication too much, or when they 
provide portions of their dosage to acquaintances.  Ensuing 
problems arise with diversion, misuse, and unintended 
exposure resulting in accidental poisoning. Probuphine was 
designed to address these problems, but the medication must 
proceed through the regulatory approval process, involving 
extensive research. A recent publication in October 2010 was 
a major step in that direction, documenting the effectiveness 
of Probuphine, thus offering a means to curtail the problems 
of adherence, diversion, misuse, and accidental poisoning 
associated with sublingual buprenorphine.23
Many clinicians and prospective patients have high expec-
tations of Probuphine, just as they did for buprenorphine. Such 
potential can be hard to live up to; in the short run, Probuphine 
must continue through the approval gauntlet and ultimately be 
tested in community-based practice with real patients before 
its “success” is confirmed. The steady progress in develop-
ment continues, and the manufacturer (Titan Pharmaceuticals, 
Brooklyn, NY) is expected to file a New Drug Application 
soon. Eventual FDA approval of Probuphine will enable 
provision of an effective means to counter the problems of 
medication adherence, diversion, and accidental poisoning 
associated with sublingual buprenorphine.
Depot delivery of medications has always been contro-
versial, so the continued debate about depot naltrexone is 
not surprising. Announcement of FDA approval of Vivitrol 
and release of supportive research documentation sparked a 
heated debate in the literature and among clinicians around 
the world, raising such issues as potential overdose among 
Vivitrol-treated individuals who use opioids soon after the 
antagonist effects wane following cessation, and a possible 
range of side effects that could inhibit patients’ willingness to 
comply with subsequent Vivitrol injections. The Russian trial 
(which was the basis for FDA approval of Vivitrol) indicated a 
generally good tolerability and retention in treatment, and the 
results would not categorically be considered inapplicable to 
other opioid addicts. Still, the findings should be replicated in 
locales where patients have other options for treatment, includ-
ing opioid agonist and partial agonist medications. Research 
has not been conducted to inform which patient populations 
may be best suited to long-term antagonist treatments, though 
some highly motivated subpopulations such as physicians 
have had good clinical outcomes with long-term treatment 
with oral naltrexone. The availability of  sustained-release 
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naltrexone should facilitate such long-term treatment but it 
is too early to know this from current research.
Implications regarding HIv among  
opioid-using populations
A particularly important aspect of buprenorphine is its com-
patibility with HIV antiretroviral therapies. The literature 
indicates fewer interactions between buprenorphine and HIV 
medications than have been documented with methadone 
and HIV medications.60,61 Although interactions between 
buprenorphine and some HIV/AIDS medications do have 
the potential to alter buprenorphine levels, the effects do not 
appear clinically significant for most of the HIV medications. 
Monitoring buprenorphine dose levels in the presence of such 
medications is advised in Treatment Improvement Protocol 
Series 40.62 Buprenorphine is the preferred medication for 
comorbid opioid dependence and HIV/AIDS, given the ability 
of a treating clinician to care medically for an HIV-infected 
patient and also prescribe the less restricted partial agonist 
therapy. The Probuphine form of buprenorphine offers addi-
tional benefits in this regard, where its ensured delivery over 
an extended period can help stem opioid use that involves 
behaviors that increase risk of HIV transmission. Similarly, 
Vivitrol can be considered an important medication advance 
in the struggle to halt transmission of HIV, because its month-
long effect helps reduce opioid use and related risky behaviors. 
The promotion of addiction medications in developing coun-
tries as a means of helping to curtail HIV/AIDS is particularly 
important, as noted below.
Implications for implementation of 
addiction treatment in developing regions
In the Western “first world” nations, the development of 
new pharmacotherapies and improvements to current opioid 
addiction treatments are natural steps toward more efficient, 
more effective, and more palatable approaches to treating 
addiction. In contrast, the developing countries are in many 
cases completely lacking in addiction treatment infrastruc-
ture, having very little clinical experience with medications 
and logistics of addiction treatment. Thus, some of the 
innovations in medications that have been long used in most 
 European and North American nations could be considered 
“new” therapies that might be usable by clinicians in the 
countries lacking previous expertise with the older phar-
macotherapies such as methadone and naltrexone. Such a 
“leapfrogging” of older therapies may be feasible in countries 
with supportive contextual features, such as China, with a 
large national health system. Nations with limited resources 
and with few clinicians familiar with addiction treatment of 
any kind may need to progress through the traditional steps 
of implementing early-version medications before being able 
to make use of the newly developed pharmacotherapies.
An important consideration regarding treatment of opioid 
addiction in the developing countries is the high rate of HIV/
AIDS among addicts, which means that clinicians must be 
increasingly concerned with potential drug/drug interactions 
involving antiretroviral agents and addiction medications. 
In many areas, such as China, methadone is the primary 
or only addiction medication that is available thus far, and 
methadone can be a problem in the presence of HIV/AIDS 
pharmacotherapies. As noted above, buprenorphine would 
be the preferred addiction medication, but regulatory cir-
cumstances and political policies may preclude adoption of 
the partial agonist due to its potential for misuse, diversion, 
and noncompliance.
Conceivably, a superior medication that can be safely 
used in conjunction with HIV/AIDS pharmacotherapies 
would prevail, but in the case of countries with long-standing 
policies against opioid “substitution” such as with methadone 
or buprenorphine, resistance to buprenorphine may persist. 
The anticipated availability of Probuphine represents an 
attractive alternative that should be palatable to most cultures. 
In places where even Probuphine might be rejected, such as 
where “therapy” for opioid addiction is limited to long-term 
forced abstinence in labor camps or “rehabilitation centers,” 
Vivitrol may be the useful pharmacotherapy to prevent 
relapse to opioid use after such “treatment”.
Summary
The problem of opioid addiction will not go away on its own, 
and treatments must continue to be developed and made 
workable and cost-effective for a range of circumstances 
and for a variety of addict populations. Some developing 
countries may become the early adopters of innovative 
pharmacotherapies sooner than some Western nations if such 
approaches can be proven effective, thereby enabling bypass-
ing older medications that never gained a foothold as they did 
in the West. Meanwhile, researchers and clinicians around 
the world must keep advancing the science and practice to 
improve what we have while looking toward the horizon 
for new discoveries and developments in pharmacotherapy, 
behavioral therapy, and neuroimmunology.
While such research and practice improvement efforts 
continue, controversies and concerns will emerge in tandem 
with advances. Reluctance to adopt and implement new 
medications and procedures can be expected, and expressions 
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of caution are important considerations in the regulatory 
process and in the course of implementation. Best practices 
and optimized outcomes will emerge from continued devel-
opment efforts that take into account input from the full 
range of stakeholders.
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